Published in Urology on August 16, 2010
A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol (2013) 1.48
Outcomes and complications of pelvic lymph node dissection during robotic-assisted radical prostatectomy. World J Urol (2013) 0.89
Pelvic lymph node dissection for patients with elevated risk of lymph node invasion during radical prostatectomy: comparison of open, laparoscopic and robot-assisted procedures. J Endourol (2011) 0.89
Australian patterns of prostate cancer care: Are they evolving? Prostate Int (2015) 0.81
Why all prostate cancer surgery should include an adequate lymph node dissection. Can Urol Assoc J (2010) 0.75
Suboptimal use of pelvic lymph node dissection: Differences in guideline adherence between robot-assisted and open radical prostatectomy. Can Urol Assoc J (2016) 0.75
A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med (2009) 25.01
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet (2008) 14.07
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA (2011) 7.61
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol (2011) 4.60
The intensity and variation of surgical care at the end of life: a retrospective cohort study. Lancet (2011) 4.44
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med (2003) 4.30
Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol (2008) 4.23
Simulation-based trial of surgical-crisis checklists. N Engl J Med (2013) 4.14
The reliability of medical record review for estimating adverse event rates. Ann Intern Med (2002) 4.02
Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol (2011) 3.96
Global operating theatre distribution and pulse oximetry supply: an estimation from reported data. Lancet (2010) 3.84
The digital divide in adoption and use of a personal health record. Arch Intern Med (2011) 3.69
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
Association between congenital cardiovascular malformations and neuroblastoma. J Pediatr (2004) 3.55
Changes in medical errors after implementation of a handoff program. N Engl J Med (2014) 3.50
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med (2004) 3.50
Crisis checklists for the operating room: development and pilot testing. J Am Coll Surg (2011) 3.19
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA (2009) 3.10
Patterns of communication breakdowns resulting in injury to surgical patients. J Am Coll Surg (2007) 3.09
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Use, costs and comparative effectiveness of robotic assisted, laparoscopic and open urological surgery. J Urol (2012) 2.94
Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 2.85
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Hospital volume, utilization, costs and outcomes of robot-assisted laparoscopic radical prostatectomy. J Urol (2012) 2.79
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Comparative effectiveness of perineal versus retropubic and minimally invasive radical prostatectomy. J Urol (2010) 2.77
Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol (2004) 2.68
Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys (2007) 2.55
Rates of medical errors and preventable adverse events among hospitalized children following implementation of a resident handoff bundle. JAMA (2013) 2.52
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Influence of surgeon and hospital volume on radical prostatectomy costs. J Urol (2012) 2.37
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. Urology (2011) 2.24
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol (2009) 2.23
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. BJU Int (2013) 2.18
Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology (2013) 2.16
Changes in safety attitude and relationship to decreased postoperative morbidity and mortality following implementation of a checklist-based surgical safety intervention. BMJ Qual Saf (2011) 2.16
Risks of complications by attending physicians after performing nighttime procedures. JAMA (2009) 2.16
Effect of a 19-item surgical safety checklist during urgent operations in a global patient population. Ann Surg (2010) 2.14
Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14
The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med (2004) 2.11
Stepwise approach for nerve sparing without countertraction during robot-assisted radical prostatectomy: technique and outcomes. Eur Urol (2011) 2.09
Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria. Int J Urol (2014) 2.08
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int (2011) 2.07
Comparison of outpatient narcotic prescribing patterns after minimally invasive versus retropubic and perineal radical prostatectomy. J Urol (2011) 2.05
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol (2011) 2.02
Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol (2010) 2.00
Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys (2013) 2.00
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol (2012) 2.00
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol (2011) 1.99
Thrombosed external hemorrhoids: outcome after conservative or surgical management. Dis Colon Rectum (2004) 1.94
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol (2012) 1.86
Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer (2011) 1.85